Adult T cell leukemia lymphoma ATLL is a highly aggressive peripheral T-cell neoplasm associated with infection by a specific retrovirus, human T-cell lymphotropic virus type-HTLV-. 1,2 This hematological malignancy is resistant to conventional chemotherapy, and has a poor prognosis. Two previous multicenter trials for ATLL Japan Clini- Adult T cell leukemia／lymphoma（ATLL）is an aggressive peripheral T-cell neoplasm. Humanized anti-CC chemokine receptor 4 monoclonal antibody（mogamulizumab）has been shown to be effective for relapsed／refractory ATLL. However, the effects of mogamulizumab application before allogeneic stem cell transplantation are uncertain. Here, we present an ATLL patient who was administered mogamulizumab and suffered from refractory acute graft-versus-host disease（GVHD）following umbilical cord blood transplantation（UCBT） . This was accompanied by delayed reconstitution and a long-lasting reduction of regulatory T cells（Tregs） . We suggest that this attenuation of Tregs influenced the clinical course of the severe／refractory GVHD following UCBT in a patient pretreated with mogamulizumab therapy. （Journal
Introduction

Human herpesvirus 6 (HHV6) is a member of the herpesvirus subfamily. 1 Primary HHV6 infection is recognized as a cause of exanthema subitum and acute febrile illness. More than 90% of the general population has been infected with HHV6, mostly during early childhood. 2 After primary infection, HHV6 remains latent in the host.
Occasionally, it may be reactivated later in life under immunosuppressive conditions, including post-allogeneic hematopoietic stem cell transplantation (HSCT). 3 HHV6
replication occurs in approximately half of allogeneic HSCT recipients and may cause fever, skin rash, interstitial pneumonia, and encephalitis. 4, 5 To date, however, HHV6-associated pleurisy has not been recognized as a complication of HSCT. In this report, we describe an adult HSCT recipient who developed HHV6-associated pleurisy after an unrelated cord blood transplantation (CBT).
Case report
The subject of this report is a 45-year-old man diagnosed as 
Flow cytometric analysis
We analyzed CD4, CD25, and Forkhead box protein 3
FoxP3 expression on peripheral blood mononuclear cells PBMC after UCBT. Protocol-specified immunophenotypic analyses were performed by flow cytometry as described previously. 9 Tregs were defined as CD4 CD25 FoxP3 cells as shown in Figure 2 
Measurement of plasma mogamulizumab concentrations
The concentration of mogamulizumab in the patient s serum was measured by Kyowa Hakko Kirin Co., Ltd.
Tokyo, Japan using their enzyme-linked immunosorbent assay system.
Results
Measurement of Tregs population and plasma mogamulizumab concentrations
As shown in Figure 3 
Discussion
Tregs are a subset of T cells defined by coexpression of CD4, CD25, and transcription factor FoxP3, which suppress autoreactive lymphocytes, and control innate and adaptive immune responses. 10 These cells might be affected by the anti-CCR4 antibody mogamulizumab, because CCR4 is There is some concern that mogamulizumab administered as an induction therapy prior to allo-HSCT might delay the reconstitution of Tregs and cause severe refractory GVHD, because it has been shown that Tregs reduce GVHD severity. 12, 13 In general, Tregs account for approximately 5 to 10%
of circulating CD4 T cells; this normal proportion of Tregs is usually recovered after allo-HSCT within only one month. FOXP3 cells after the first mogamulizumab infusion. 7 Determining the optimum number of mogamulizumab administrations before allogeneic stem cell transplantation is a future task.
When she was diagnosed with acute-type ATLL with duodenal involvement, tumor cells were not detected in colonic mucosa, which was confirmed on random biopsy of the colon.
Since she developed severe diarrhea, there was the potential 
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